RxDoctor Payments Data

Anna Lincheck

Family · Rockford, ILNPI 1841660479

Payments from drug & device makers

$7,676in general payments, 2019–2025

Across 440 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$1K
  • Amgen$667
  • Boehringer Ingelheim$523
  • Esperion Therapeutics, Inc.$407
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$7,34396%
  • Education$3334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,676 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$62,335
Medicare patients
431
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$62,123
XareltoRivaroxaban37$58,853
JardianceEmpagliflozin26$30,781
Repatha SureclickEvolocumab29$23,160
EntrestoSacubitril/Valsartan14$18,780
Ranolazine ErRanolazine32$2,504
Ezetimibe113$2,501
Metoprolol Succinate155$1,823
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$1,329
Atorvastatin Calcium136$1,285
Losartan Potassium56$739
Metoprolol Tartrate96$682
Bumetanide24$640
Rosuvastatin Calcium70$567
Carvedilol67$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$62,12361 claims
Johnson & JohnsonXarelto$1,642$58,85337 claims
Boehringer IngelheimJardiance$523$30,78126 claims
NovartisEntresto$1,050$18,78014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →